Increasing evidence points to DGKα as a critical node in oncogenic signaling and as a putative novel therapeutic target in cancer: inhibition or silencing of DGKα has been shown to reduce tumor growth and mortality in glioblastoma and hepatic carcinoma xenograft models [13], [14]. The gene discussed is DGKA; the disease is hepatocellular carcinoma.